Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

Latest News

Liverpool returns to top spot; Everton humiliates Man United

Apr 22, 2019

LONDON — Before returning to the top of the Premier League, Liverpool got to savor a Manchester United humiliation. Now, unusually, Liverpool needs a swift recovery by its great rival after United's despair at being routed 4-0 by Everton on Sunday. Liverpool's hopes of ending a 29-year English title drought could hinge on a big favor from sixth-place United when it hosts Manchester City on Wednesday. After beating Cardiff 2-0 on Sunday, Liverpool is two points ahead of City with three games remaining. But Pep Guardiola's champions have a game in hand over Liverpool so defending the title is still...

Arsenal top-4 bid dented by 3-2 home loss to Crystal Palace

Apr 22, 2019

LONDON — Christian Benteke's first goal in almost a year set Crystal Palace on its way to a 3-2 victory at Arsenal in the Premier League on Sunday, denting the north London club's top-four bid. After Benteke netted his first goal in 20 games in the 17th minute, Mesut Ozil equalized at the start of the second half. But Benteke set up Wilfried Zaha to restore Palace's lead in the 61st before James McArthur headed in the visitors' third. Pierre-Emerick Aubameyang scored in the 77th but Arsenal couldn't find two more goals to extend its 10-match winning league run at...

Sterling, Van Dijk among England's player of year contenders

Apr 22, 2019

LONDON — Premier League title contenders Liverpool and Manchester City dominate the six-man shortlist for the Professional Footballers' Association player of the year award, with defender Virgil van Dijk and forward Raheem Sterling the front-runners. Van Dijk joins Liverpool teammate Sadio Mane on the list, while Sterling is included alongside fellow City players Sergio Aguero and Bernardo Silva after voting by fellow professionals. Chelsea winger Eden Hazard completes the nominees, with the winner announced on April 28. Sterling and Silva, both 24, also make the shortlist for the young player of the year award. They are joined in that category...

Brazilian tennis player Souza provisionally suspended

Apr 22, 2019

LONDON — Brazilian tennis player Joao Souza has been provisionally suspended again amid a corruption investigation by the Tennis Integrity Unit. Souza had already been provisionally suspended on March 29 but was reinstated on April 8 following a successful appeal. The TIU says that the provisional suspension has been put back in place "following consideration of additional evidence submitted by the TIU," adding that no more appeals will be accepted. No further details were given for the reason of the suspension. The 30-year old Souza is currently ranked No. 422, having reached a career-high of No. 69 in 2015. Also...

Archer misses out on England's preliminary World Cup squad

Apr 22, 2019

LONDON — Jofra Archer was left off England's preliminary 15-man squad for the Cricket World Cup, a month after the paceman qualified to play for the country on residency rules. Archer was, however, called up for England's warm-up games against Pakistan and Ireland, where impressive performances could yet earn him a late spot in the World Cup squad. England plays Ireland on May 3, then begins a five-match ODI series against Pakistan on May 8. The 24-year-old Archer, who was born in Barbados but has an English father and holds a British passport, completed a three-year qualification period on March...

About Us

Frontal Report is an emerging leader in all forms of media. We aim to be the leading news brand for readers around the world.

Contact us: sales[at]frontalreport.com

Subscribe Now!